...Inception that does not follow the build-to-buy model (see BioCentury, March 28) . Lead candidate TPST-8844... ...Robert Weisskoff and Quan's Stella Xu joined Tempest's board.
Virginia Li
Indoleamine 2,3-dioxygenase (IDO) (INDO)
PPAR alpha
Tempest Therapeutics Inc.
TPST-1120
TPST-8844
Versant...
...testing, and a third into the clinic, in the next three years. The most advanced, TPST-8844... ...the clinic in the next 12 months. CEO Tom Dubensky said Tempest plans to evaluate TPST-8844... ...Highline Therapeutics (see BioCentury, Feb. 27) .
Virginia Li, Assistant Editor
Indoleamine 2,3-dioxygenase (IDO) (INDO)
PPAR alpha
Tempest Therapeutics Inc.
TPST-1120
TPST-8844
Versant...
